Alphatec Holdings, Inc. (ATEC)

Alphatec Holdings, Inc. (ATEC) stock has experienced significant positive momentum over the past year, with returns ranging from 188.1% to 215.94%. The stock reached a 52-week high of $16.71 on October 27, 2025. Key events impacting the stock price include robust Q2 2025 earnings, where the company reported total revenue of $186 million, a 27% increase year-over-year, and raised its full-year revenue guidance for 2025 to $742 million. JPMorgan initiated coverage on Alphatec Holdings with an "Overweight" rating and a $19.00 price target, citing the company's business transformation and strong double-digit growth. Analysts, in general, have given the stock an average rating of "Moderate Buy," with eight buy ratings and one sell rating. Despite this strong performance, the stock experienced a 6.1% pullback in March 2025, which added to one-year losses at that time.

Alphatec Holdings, Inc. experiences some demand seasonality for its products and services. The company's management has noted a "seasonal Q2-to-Q3 step down" in earnings calls.

Alphatec Holdings, Inc. is a medical technology company in the healthcare sector, specifically the medical devices and instruments industry, focused on revolutionizing spine surgery through innovative solutions. The company designs, develops, and markets a comprehensive portfolio of products for the surgical treatment of spinal disorders, including spinal implants, advanced surgical instruments like the SafeOp Neural InformatiX System, and a biologics portfolio. Its Alpha InformatiX product platform integrates technologies such as the EOS imaging system, the VEA alignment mobile application, and Valence, an intra-operative system that combines navigation and robotics into spine procedures. Other offerings include procedure-specific access systems like the Sigma-ALIF Access System and PTP Patient Positioning Systems.

Alphatec Holdings, Inc. operates in the United States and internationally. The company is actively exploring opportunities to expand its presence in international markets and has identified expanding early commercial efforts in these markets as a growth opportunity. In 2016, the company underwent a divestiture of its international business, indicating a strategic shift and a renewed focus on global expansion.

Alphatec Holdings, Inc. maintains a positive brand reputation, largely driven by its focus on innovation and commitment to improving patient outcomes in spine surgery. The company has garnered positive sentiment due to its expanding product portfolio and targeted acquisitions. Its advancements in integrating navigation and robotics into spinal surgeries, along with the launch of new platforms like the Prone TransPsoas (PTP™) Corpectomy System, have set it apart in the competitive spine care industry. Stifel reinstated coverage of Alphatec with a "Buy" rating, recognizing the company for anticipated market share growth in the U.S. spine surgery sector, further reinforcing its positive standing. No specific events negatively impacting Alphatec Holdings, Inc.'s reputation in the past year were found in the search results.

Alphatec Holdings, Inc. has a diverse ownership structure, with a significant portion held by institutional investors, ranging from approximately 61% to 68.73% of the company's stock. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, American Century Companies Inc, UBS Group AG, Royal Bank Of Canada, BNP Paribas Asset Management Holding S.A., State Street Corp., Zions Bancorporation NA, Schweizerische Nationalbank, SEI Investments Co., and Manulife Financial Corp. Individual insider ownership is also notable, ranging from 12% to 17.67%. CEO Patrick Miles holds 3.6% of the company's shares, and David R Pelizzon is noted as owning the most shares among individuals. Squadron Capital, LLC and LS Power Development, LLC have also been identified as large shareholders.